The use of Ru complexes in light-mediated treatment of cancer (i.e. Photodynamic Therapy-PDT) has recently become extremely relevant with the entry into clinical trials of the first complexof this class against bladder cancer. Herein, we report on the potential application as PDT agents of two inertRu(II) polypyridyl complexes bearing a nitrile containing dppz ligand and two bipy or phenancillary ligands for 1 and 2, respectively (dppz = dipyrido[3,2-a:2′,3′-c]phenazine,bipy = 2,2'-bipyridine, phen = 1,10phenathroline).More specifically, a full characterization of the novel compound 2 was first performed. The distribution coefficients (logD) and 1 O 2 quantum yields in two solvent systems and at two irradiation wavelengths were then determined for both compounds. The phototoxicity of complexes 1 and 2was evaluated on cervical cancer HeLa cells and on non tumorigenic retinal pigment epithelial (RPE1-hTERT) cells. None of the complexes was found to be phototoxic.In vitro fluorescence microscopy indicated a scarce cellular uptake for 2. The lack of biological activity for complexes1 and 2 highlightsthat more investigations are required in order to understand the relationship between structure and biological activity for this class of compounds. 1 Introduction The application of ruthenium complexes as biologically active compounds was thoroughlyinvestigatedin the last decades. Two Ru(III) complexes are currently undergoing Phase II clinical trials as anticancer agents(i.e. NAMI-A and KP-1339) and a Ru(II) organometallic complex is under clinical optimization (i.e. RAPTA-C). [1-4] The complexes which are under evaluation are characterized by a mechanism of cytotoxicity based on ligand exchange. Another class of Ru compounds, namely substitutionally inert Ru(II) polypyridyl complexes, is characterized by favourable photophysicalproperties that make these complexesattractive for applicationssuch as photosensitizers (PSs) in Photodynamic Therapy (PDT) and Photoactivated Chemotherapy (PACT). [5] The use of such complexes for light-mediated treatment of cancer has thoroughly been investigated in the last years. [5] As a highlight of this research, a Ru(II) polypyridyl compound will be soon tested as a PDT agent in the clinics against non-muscle invasive bladder cancer (TLD-1433, Figure 1). [6] Several reasons make this type of compounds usefulin this field of research. For example, they display a strong absorbance in the visible region of the electromagnetic spectrum. Moreover, they are characterized by a reasonably long-lived triplet excited state. This allows for energy transfer to triplet oxygen (3 O 2) to form the toxic singlet oxygen (1 O 2).However, in this recent and promising research area, there is still a great room for optimization. For example, it would be highly desirable to have novel PSs with enhanced biological activity and/or activation wavelengthsin the PDT window (650-900 nm) and/orpossibly O 2-independent mechanisms of action.Our group has investigated the potential of Ru(II) polypyridyl compounds as dr...